EU IVDR Audit Bottlenecks Are Redrawing Market Access

Stricter EU IVDR audits are making certification capacity and compliance execution the new bottlenecks for IVD market access.

Updated

What is this trend?

EU IVDR audit and evidence requirements are turning notified-body capacity, QMS readiness, and batch-release testing into the main gatekeepers of IVD market access.

  • Class B/C/D devices face deeper audits, with Class D adding EU reference lab batch-release testing.
  • Extended-transition filings now require formal notified-body applications and signed agreements on deadline.
  • Technical documentation, QMS evidence, and post-market follow-up matter more than assay novelty.
  • Audit capacity is becoming a commercial constraint that can delay certification and revenue.
  • Approved-supplier status and repeat audit performance are emerging as competitive advantages.

What’s the latest?

EU IVDR readiness turned into a hard commercial gate this week: Class B, C, and D devices now face deeper notified-body involvement, with Class C requiring a full quality-system audit and Class D addi

Therapy-Specific Liquid Biopsy, Routed Telepathology, and Workflow-Control AI Tighten Diagnostic Control

How it developed

  1. Serial reimbursement, distributed biomarker workflows, and FDA-cleared claims are reshaping diagnostics commercialization
    • FDA-Cleared Claims Are Becoming Commercial Moats

  2. Workflow-embedded diagnostics win, EU access bottlenecks tighten, and biomarker evidence becomes the moat
    • EU IVDR Audit Bottlenecks Are Redrawing Market Access

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in Diagnostics & Informatics

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.